| 1T3 Stock | | | EUR 12.80 0.10 0.78% |
Founder
Peter BSc is CoFounder Officer of Syndax Pharmaceuticals
| Age | 54 |
| Phone | 781 419 1400 |
| Web | https://www.syndax.com |
Syndax Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
(0.0292) % which means that it has lost $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.0519) %, meaning that it generated substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Syndax Pharmaceuticals has accumulated 19.89
M in total debt with debt to equity ratio
(D/E) of 1.9, which is about average as compared to similar companies. Syndax Pharmaceuticals has a current ratio of 6.12, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Syndax Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Syndax Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Syndax Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Syndax to invest in growth at high rates of return. When we think about Syndax Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Syndax Pharmaceuticals operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 38 people. Syndax Pharmaceuticals (1T3) is traded on Frankfurt Exchange in Germany and employs 59 people.
Management Performance
Syndax Pharmaceuticals Leadership Team
Elected by the shareholders, the Syndax Pharmaceuticals' board of directors comprises two types of representatives: Syndax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syndax. The board's role is to monitor Syndax Pharmaceuticals' management team and ensure that shareholders' interests are well served. Syndax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syndax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Briggs MD, Head Pres | |
| Michael MBA, CEO Director | |
| Ronald Evans, Advisor CoFounder | |
| Sharon Klahre, VP Communications | |
| Peter BSc, CoFounder Officer | |
| Richard Heyman, CoFounder | |
| Anjali Ganguli, Chief Officer | |
| Alexander Nolte, VP Officer | |
| Keith CPA, Chief Officer | |
| Michael Downes, CoFounder | |
Syndax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syndax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Syndax Stock
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals'
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Syndax Stock please use our
How to Invest in Syndax Pharmaceuticals guide.
You can also try the
Transaction History module to view history of all your transactions and understand their impact on performance.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.